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Abstract: We present a case of inflammatory abdominal arterial aneurysms, which demonstrates the po-
tential usefulness of PET/CT with F-FDG in long-term monitoring of this disease, but also demonstrates
potential pitfalls in abdominal arterial aneurysm imaging with PET/CT. Imaging may be challenged as
the initial presentation prior to therapy may mimic an infected aneurysm. Follow-up images may be
mistaken for vascular graft infection or persistent disease.
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Abstract:We present a case of inflammatory abdominal arterial aneurysms,
which demonstrates the potential usefulness of PET/CT with 18F-FDG in
long-termmonitoring of this disease, but also demonstrates potential pitfalls
in abdominal arterial aneurysm imaging with PET/CT. Imaging may be
challenged as the initial presentation prior to therapy may mimic an infected
aneurysm. Follow-up images may bemistaken for vascular graft infection or
persistent disease.
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FIGURE 1. Inflammatory abdominal arterial aneurysms (IAA) are characterized by perianeurysmal fibrosis and inflammation and
constitute between 3% and 10% of all abdominal aneurysms. Etiology, pathogenesis, patient management, and the duration
of anti-inflammatory therapy are discussed controversially in the literature. Positron emission tomography/computed tomography
with 18F-fluorodeoxyglucose (PET/CT) has become a promising imaging modality in the field of infection and inflammation,
particularly in vascular diseases such as arteritis and vascular graft infections. Images demonstrate the case of a 58-year-old man,
who initially presentedwith back pain and fever. TheC-reactive proteinwas 44mg/L, and thewhite blood cell countwas 7.4G/L.
His initial PET/CT examination in February 2015 (maximum intensity reconstructions of PET [A] and fused PET/CT images [E])
showed intensely increased FDG uptake in the wall of an abdominal aortic aneurysm (SUVmax 9.0). This finding was rated
suggestive of an infected arterial aneurysm by 2 experienced PET/CT readers; however, the final diagnosis was an immunoglobulin
G4–associated inflammatory abdominal aneurysm (Ormond disease). At first PET/CT follow-up after endovascular repair in
September 2015 (B and F), the patient was under ongoing steroid treatment and no antibiotic treatment; the C-reactive protein
had decreased to 25mg/L, and the white blood cell count was 7.6 G/L. An intense focal FDG uptake (SUVmax 7.2) was detected
adjacent to the graft, which fulfilled all imaging criteria for a vascular graft infection.1Consecutive follow-up PET/CT inMarch 2016
and December 2017 showed very faintly increased FDG uptake (C,D,G, andH), slightly higher than background activity in the
mediastinal blood, but lower than background activity in the liver. This is in line with previous reports on therapy control in vascular
graft infection, describing faint residual metabolic activity adjacent to the graft, even after successful antibiotic treatment.2 At the
last clinical follow-up in December 2017, the patient was in good clinical condition, treated with low-dose prednisone (5 mg/d),
and showed no sign of infection. This case report documents that IAA may present with high metabolic activity in PET/CT,
comparable to infected aneurysms3,4 or vascular graft infections.1,2,5–8 Previous reports on vascular graft infections have shown that
the metabolic activity typically decreases with antibiotic treatment.2,9–14 However, metabolic activity may remain above
background level even after successful treatment.2 Similarly, in patients with IAA, therapy control with PET/CT may potentially
mimic persistent disease.
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